Hormones, Genes, and Cancer

Hormones, Genes, and Cancer PDF

Author: Brian E. Henderson

Publisher: Oxford University Press

Published: 2003-03-13

Total Pages: 467

ISBN-13: 0199771588

DOWNLOAD EBOOK →

Hormonal carcinogenesis is an important and controversial area of current research. In addition to accelerating existing cancers, can hormones play the role of primary carcinogens? How do genetic factors influence hormone-related cancer risk? Hormones, Genes, and Cancer addresses these questions. Over the past few decades, cancer research has focused on external environmental causes(e.g., tobacco smoke, viruses, asbestos). With the advent of new genetic sequencing techniques, we are just now beginning to understand how the body's internal environment(i.e., the hormones and growth factors that determine normal development) influences cancer etiology and prevention. From molecular insights to clinical analyses, this volume provides state-of-the-art information on the complex interactions between hormones and genes and cancer. The epidemiology and molecular endocrinology of prostate, breast, uterine, ovarian and testicular cancer are detailed in this timely treatise.

Hormones, Genes, and Cancer

Hormones, Genes, and Cancer PDF

Author: Brian E. Henderson

Publisher:

Published: 2023

Total Pages: 0

ISBN-13: 9780197707128

DOWNLOAD EBOOK →

Hormonal carcinogenesis is an important and controversial area of research. In addition to accelerating existing cancers, can hormones play the role of primary carcinogens? And how do genetic factors influence hormone-related cancer risk? This work addresses these questions.

Genes, Oncogenes, and Hormones

Genes, Oncogenes, and Hormones PDF

Author: Robert B. Dickson

Publisher: Springer Science & Business Media

Published: 2012-12-06

Total Pages: 478

ISBN-13: 146153500X

DOWNLOAD EBOOK →

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, and easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc.; and second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current di agnosis, staging, markers, all forms of treatment modalities, basic biology, and more.

Hormones and Cancer

Hormones and Cancer PDF

Author: Wayne V. Vedeckis

Publisher: Springer Science & Business Media

Published: 2012-12-06

Total Pages: 618

ISBN-13: 1461242665

DOWNLOAD EBOOK →

The series, Hormones in Health and Disease, was launched in 1993 to provide a scientific platform for investigators engaged in research on the biological actions of hormones and to anticipate relevance for their findings in clinical applications. The first volume of the series was dedicated to the discussion and understanding of molecular mechanisms by which steroid hormones influence target cells in normal and pathological conditions. With the diversity of information and the vast amount of literature on steroid hormone physiology, a more thorough treatment of Hormones and Cancer was identified as a timely topic. In this second volume in the series, Dr. Wayne V. Vedeckis has success fully undertaken the monumental task of editing the findings of the leading investigators in hormone and cancer research. Dr. Vedeckis brings to this project two decades of research experience in hormone action; he is actively engaged in elucidating hormone and cancer interrelations. It is a pleasure to welcome him to the series as an editor and congratulate him and all contribu tors in presenting this comprehensive treatise. The 20 chapters include discussions on contemporary topics relating control of cell division and signal transduction to the basic mechanisms of carcinogenesis by cloning patient genes, and recognizing the importance of steroid receptors in treatment protocols of various endocrine abnormalities.

Hormonal Carcinogenesis III

Hormonal Carcinogenesis III PDF

Author: Jonathan J. Li

Publisher: Springer Science & Business Media

Published: 2012-12-06

Total Pages: 610

ISBN-13: 1461220920

DOWNLOAD EBOOK →

Since our previous symposium in 1995, the pace of research in hormones and cancer has accelerated. Progress in our understanding of hormonal carcinogenic processes has been a direct result of the advances made in cell biology, endocrinology, and carcinogenesis at the molecular level. The newer fields of molecular genetics and cytogenetics already have and are expected to continue to playa major role in furthering our understanding of the cellular and molecular events in hormonal carcinogenesis. It has become increasingly clear that the risk of naturally occurring sex hormones in carcinogenic processes, both in human and in animal models, requires only minute quantities of hormones, at both the serum and tissue levels. Moreover, hormone target tissues for neoplastic transformation, perhaps with the exception of the liver, generally have relatively modest ability to metabolize sex hormones, such as the breast and prostate. Table 1 summarizes the serum, and in most cases, the tissue levels of sex hormones, both endogenously and exogenously ingested, which are associated with increased risk for endocrine-associated cancers such as breast, endometrium, and prostate, as well as the hormone levels of four experimental models that have been shown to elicit high tumor incidences. In contrast to the human, in which the hormone levels are cyclic, however, the latter require continuous hormone exposure at these relatively low levels.

Hormonal Carcinogenesis V

Hormonal Carcinogenesis V PDF

Author: Jonathan J. Li

Publisher: Springer Science & Business Media

Published: 2008-04-24

Total Pages: 647

ISBN-13: 0387690808

DOWNLOAD EBOOK →

Information gathered from cell-free systems, cell cultures, animal models, and human studies, together provide important insights to our understanding of hormonal cancer causation, development, and prevention; the primary objective of these Symposia. A special emphasis is placed on the two major endocrine-related cancers, that is, breast and prostate. The emerging fields of colon, lung, and pancreatic cancers in relation to hormones are examined.

Cancer and the Environment

Cancer and the Environment PDF

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2002-08-01

Total Pages: 160

ISBN-13: 0309169240

DOWNLOAD EBOOK →

The Roundtable on Environmental Health Sciences, Research, and Medicine wanted to address the link between environmental factors and the development of cancer in light of recent advances in genomics. They asked what research tools are needed, how new scientific information can be applied in a timely manner to reduce the burden of cancer, and how this can be flexible enough to treat the individual.

Testis cancer: genes, environment, hormones

Testis cancer: genes, environment, hormones PDF

Author: Alberto Ferlin

Publisher: Frontiers Media SA

Published: 2015-10-29

Total Pages: 88

ISBN-13: 2889196720

DOWNLOAD EBOOK →

Testicular cancer (TC) is the most common cancer in males aged 20-40 years, with a worldwide incidence of 7.5 per 100,000, but the rates vary considerably between countries and ethnic groups and there is evidence also for an increasing incidence in last decades. About 95% of all TCs are represented by testicular germ cell tumors (TGCTs), which include seminoma and non-seminoma histological types. It is generally assumed that the development of TGCT is under endocrine control. In particular, unbalanced androgen/estrogen levels and/or activity are believed to represent the key events for TGCT development and progression. Furthermore, recent evidence has suggested genetic association of TGCT with variations in genes involved in hypothalamic-pituitary-testicular axis and steroidogenic enzymes. This recent evidence expands the current knowledge on the role of genetic contribution in testicular cancer susceptibility, and supports the hypothesis that variations in hormone metabolism genes might change the hormonal environment implicated in testicular carcinogenesis. Therefore, hormonal carcinogenesis is an important and controversial area of current research in TGCT, and further attention is given to genetic factors influencing hormone-related cancer risk. The genetic component to TGCT is in general strong. In fact, although environmental factors clearly contribute to TGCT development (and probably to its increasing incidence in some geographical areas), the proportion of TGCT susceptibility accounted for by the genetic effects is estimated at 25%. TGCT has high familial risks compared with most other cancer types that are generally no more than two-fold: brothers of individuals with TGCT have an 8- to 12-fold increased risk of disease, and sons of affected individuals have a 4- to 6-fold increased risk. Despite this strong familial relative risk, early results from linkage studies identified a limited relationship with genetic factors, suggesting that TGCT is a genetically complex trait. However, more recently, four genome-wide association studies (GWAS) from the UK and USA have reported association of TGCTs with six new loci (KITLG, SPRY4, BAK1, DMRT1, TERT, and ATF7IP). The strongest association for TGCT susceptibility was found for SNPs in KITLG (ligand for the membrane-bound receptor tyrosine kinase KIT) gene with a greater than 2.5-fold increased risk of disease per major allele, which is the highest reported for any cancer to date. These studies are being now replicated by other researches and attention is given to the relationship between these genetic variations, TGCT risk and frequently associated anomalies of the reproductive tract, such as cryptorchidism and infertility. Finally, over the past few decades, TCGT research has focused also on external environmental causes acting mainly as endocrine disrupters of androgen and oestrogen pathways, even during the foetal development of the testis. It is well known that the testicular dysgenesis syndrome (TDS) hypothesis, proposed ten years ago, suggests that disturbed testicular development in fetal life may result in one or more of four disorders postnatally, named cryptorchidism, hypospadias, poor semen quality, and TGCT. These four disorders are therefore considered as one clinical entity and are linked together by epidemiological and pathophysiological relations. The relative contribution of genetics and environment in TGCT development, and the interactions between endocrine disruptors and variations in genes involved in hormonal carcinogenesis is therefore another interesting area of research.

An Epidemiologic Study of Genetic Variation in Hormonal Pathways in Relation to the Effect of Hormone Replacement Therapy on Breast Cancer Risk

An Epidemiologic Study of Genetic Variation in Hormonal Pathways in Relation to the Effect of Hormone Replacement Therapy on Breast Cancer Risk PDF

Author:

Publisher:

Published: 2008

Total Pages: 8

ISBN-13:

DOWNLOAD EBOOK →

CHT use has been demonstrated to confer an increased risk of breast cancer. Genetic variation in hormonal pathways may modify the effect of CHT on breast cancer risk. Using 1237 cases and 1015 controls from two population-based case-control studies of breast cancer, we investigated the effect of genetic variation in 7 genes within the progesterone pathway using a tagSNP and functional SNP approach and 5 genes within the catechol estrogen pathway. Within single gene analyses we observed breast cancer risk to be modestly associated with one SNPs in each GSTP1 (rs1695: OR = 1.4 [95% CI: 1.02-1.9] for carriers of A allele); CYP1B1 (rs1056827: OR = 1.7]95% CI:1.2-2.5] for T homozygotes); SRD5A1 (rs248793: OR=1.2 [95% CI: 1.02-1.5] for G homozygotes) and PGR (rs492457: OR=1.5 [95% CI: 1.01-2.1] for carriers of the A allele). We found that the breast cancer risk associated with SNPs was particularly strong in long-term CHT users. In a multi-gene model including two genes with single gene effects within the estrogen pathway (CYP1B1*2 and GSTP1), breast cancer risk was 1.6 (95% CI: 1.03-2.4) times higher for carriers of 1 high risk genotype and 2.8 (95% CI: 1.5-5.3) times higher for women with 2 high risk genotypes compared to women with 0 high risk genotypes. The impact of high risk genotypes was stronger in long-term CHT users, particularly in long-term, current CHT users (OR=5.6 [95% CI: 1-5-20.6]). These results suggest that breast cancer risk among CHT users is modified by variation in genes within hormonal pathways.

Introduction to the Cellular and Molecular Biology of Cancer

Introduction to the Cellular and Molecular Biology of Cancer PDF

Author: Margaret Knowles

Publisher: OUP Oxford

Published: 2005-07-28

Total Pages: 564

ISBN-13: 9780191513817

DOWNLOAD EBOOK →

. What is cancer?, L.M. Franks and Margaret A. Knowles. 2. The causes of cancer, Naomi Allen, Robert Newton, Amy Berrington de Gonzalez, Jane Green, Emily Banks, and Timothy J. Key. 3. Inherited Susceptibility to Cancer, D. Timothy Bishop. 4. DNA Repair and Cancer, Beate Koberle, John P. Wittschieben, and Richard D. Wood. 5. Epigenetic Events in Cancer, Jonathan C. Cheng and Peter A. Jones. 6. Molecular Cytogenetics of Cancer, Denise. Sheer and Janet Shipley. 7. Oncogenes, Margaret A. Knowles. 8. Tumour suppressor genes, Sonia Lain and David P. Lane. 9. The cancer cell cycle, Chris J. Norbury. 10. Cellular immortalization and telomerase activation in cancer, Robert F. Newbold. 11. Growth factors and their signalling pathways in cancer, Sally A. Prigent. 12. Apoptosis: molecular physiology and significance for cancer therapeutics, Dean A. Fennell. 13. Mechanisms of Viral Carcinogenesis, Paul Farrell. 14. Cytokines and Cancer, Peter W. Szlosarek and Frances R. Balkwill. 15. Hormones and cancer, Charlotte L. Bevan. 16. The spread of tumours, Ian Hart. 17. Angiogenesis, K.Tahtis and R.Bicknell. 18. Stem cells, heamopoiesis, and leukaemia, Mel Greaves. 19. Animal models of cancer, Jos Jonkers and Anton Berns. 20. The immunology of cancer, Peter C. L. Beverley. 21. The molecular pathology of cancer, Tatjana Crnogorac-Jurcevic, Richard Poulsom, and Nicholas R. Lemoine. 22. From transcriptome to proteome, Silvana Debernardi, Rachel Craven, Bryan D. Young, and Rosamonde E. Banks. 23. Local treatment of cancer, Ian S. Fentiman. 24. Chemotherapy, D.R. Camidge and D.I. Jodrell. 25. Radiotherapy and molecular radiotherapy, Anne Kiltie. 26. Monoclonal antibodies and therapy, T. Geldart, M.J. Glennie, and P.W.M. Johnson. 27. Immunotherapy of cancer, Andrew M. Jackson and Joanne Porte. 28. Cancer gene therapy, John David Chester. 29. Screening, Peter Sasieni and Jack Cuzick. 30. Conclusions and prospects, Peter Selby and Margaret A Knowles.